TY - JOUR
T1 - Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells
AU - Nam, Jeong Seok
AU - Kang, Mi Jin
AU - Suchar, Adam M.
AU - Shimamura, Takeshi
AU - Kohn, Ethan A.
AU - Michalowska, Aleksandra M.
AU - Jordan, V. Craig
AU - Hirohashi, Setsuo
AU - Wakefield, Lalage M.
PY - 2006/7/15
Y1 - 2006/7/15
N2 - Dysadherin, a cancer-associated membrane glycoprotein, down-regulates E-cadhcrin and promotes cancer metastasis. This study examined the role of dysadherin in breast cancer progression. Expression of dysadherin was found to be highest in breast cancer cell lines and tumors that lacked the estrogen receptor (ER). Knockdown of dysadherin caused increased association of E-cadherin with the actin cytoskeleton in breast cancer cell lines that expressed E-cadherin. However, knockdown of dysadherin could still suppress cell invasiveness in cells that had no functional E-cadherin, suggesting the existence of a novel mechanism of action. Global gene expression analysis identified chemokine (C-C motif) ligand 2 (CCL2) as the transcript most affected by dysadherin knockdown in MDA-MB-231 cells, and dysadherin was shown to regulate CCL2 expression in part through activation of the nuclear factor-κB pathway. The ability of dysadherin to promote tumor cell invasion in vitro was dependent on the establishment of a CCL2 autocrine loop, and CCL2 secreted by dysadherin-positive tumor cells also promoted endothelial cell migration in a paracrine fashion. Finally, experimental suppression of CCL2 in MDA-MB-231 cells reduced their ability to metastasize in vivo. This study shows that dysadherin has prometastatic effects that are independent of E-cadherin expression and that CCL2 could play an important role in mediating the prometastatic effect of dysadherin in ER-negative breast cancer.
AB - Dysadherin, a cancer-associated membrane glycoprotein, down-regulates E-cadhcrin and promotes cancer metastasis. This study examined the role of dysadherin in breast cancer progression. Expression of dysadherin was found to be highest in breast cancer cell lines and tumors that lacked the estrogen receptor (ER). Knockdown of dysadherin caused increased association of E-cadherin with the actin cytoskeleton in breast cancer cell lines that expressed E-cadherin. However, knockdown of dysadherin could still suppress cell invasiveness in cells that had no functional E-cadherin, suggesting the existence of a novel mechanism of action. Global gene expression analysis identified chemokine (C-C motif) ligand 2 (CCL2) as the transcript most affected by dysadherin knockdown in MDA-MB-231 cells, and dysadherin was shown to regulate CCL2 expression in part through activation of the nuclear factor-κB pathway. The ability of dysadherin to promote tumor cell invasion in vitro was dependent on the establishment of a CCL2 autocrine loop, and CCL2 secreted by dysadherin-positive tumor cells also promoted endothelial cell migration in a paracrine fashion. Finally, experimental suppression of CCL2 in MDA-MB-231 cells reduced their ability to metastasize in vivo. This study shows that dysadherin has prometastatic effects that are independent of E-cadherin expression and that CCL2 could play an important role in mediating the prometastatic effect of dysadherin in ER-negative breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=33746884603&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746884603&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-06-0825
DO - 10.1158/0008-5472.CAN-06-0825
M3 - Article
C2 - 16849564
AN - SCOPUS:33746884603
SN - 0008-5472
VL - 66
SP - 7176
EP - 7184
JO - Cancer Research
JF - Cancer Research
IS - 14
ER -